Dyne Therapeutics (NASDAQ:DYN) Given New $17.00 Price Target at JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYN) had its price target reduced by stock analysts at JPMorgan Chase & Co. from $18.00 to $17.00 in a report released on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 39.57% from the company’s previous close.

Several other analysts also recently issued reports on the stock. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Scotiabank started coverage on Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. BMO Capital Markets assumed coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target for the company. Finally, Robert W. Baird started coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Trading Down 0.7 %

Shares of NASDAQ DYN traded down $0.08 during midday trading on Friday, reaching $12.18. The company’s stock had a trading volume of 533,536 shares, compared to its average volume of 1,335,016. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -3.42 and a beta of 1.11. Dyne Therapeutics has a one year low of $11.18 and a one year high of $47.45. The company has a 50 day moving average price of $13.68 and a 200 day moving average price of $24.49.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. Research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares of the company’s stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 6,237 shares of company stock worth $77,760. Corporate insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DYN. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics in the fourth quarter worth $50,000. Neo Ivy Capital Management bought a new position in Dyne Therapeutics in the 4th quarter worth $205,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Dyne Therapeutics by 6.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company’s stock valued at $3,378,000 after acquiring an additional 9,029 shares during the period. Voloridge Investment Management LLC acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $2,804,000. Finally, Two Sigma Advisers LP increased its stake in shares of Dyne Therapeutics by 25.4% in the fourth quarter. Two Sigma Advisers LP now owns 76,100 shares of the company’s stock worth $1,793,000 after purchasing an additional 15,400 shares during the period. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.